Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Academic Licensing Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: PRM013
MIFTS: 45

Premature Menopause

Categories: Reproductive diseases
Genes Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Premature Menopause

About this section

MalaCards integrated aliases for Premature Menopause:

Name: Premature Menopause 12 14 69
Menopause - Premature 12
Menopause, Premature 41
Menopause Premature 51
Menopause Praecox 12

Classifications:

MalaCards categories:
Anatomical: Reproductive diseases
See all MalaCards categories (disease lists)


External Ids:

Disease Ontology 12 DOID:10787
ICD10 32 E28.31 E28.319
ICD9CM 34 256.31
MeSH 41 D008594
NCIt 46 C80099
UMLS 69 C0025322
Sources

Summaries for Premature Menopause

About this section
MalaCards based summary : Premature Menopause, also known as menopause - premature, is related to premature ovarian failure 1 and alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity. An important gene associated with Premature Menopause is BRCA1 (BRCA1, DNA Repair Associated), and among its related pathways/superpathways are Chks in Checkpoint Regulation and DNA Damage. The drugs Progesterone and Estradiol have been mentioned in the context of this disorder. Affiliated tissues include breast, bone and ovary, and related phenotypes are Decreased viability with cisplatin and Synthetic lethal with cisplatin

Sources

Related Diseases for Premature Menopause

About this section

Diseases related to Premature Menopause via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 90)
# Related Disease Score Top Affiliating Genes
1 premature ovarian failure 1 32.2 AMH SGO2 SYCE1
2 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 30.2 TG TPO
3 thyroiditis 29.6 TG TPO
4 polyneuropathy-intellectual disability-acromicria-premature menopause syndrome 12.2
5 hereditary site-specific ovarian cancer syndrome 10.4 BRCA1 BRCA2
6 brca1 hereditary breast and ovarian cancer syndrome 10.4 BRCA1 BRCA2
7 breast reconstruction 10.4 BRCA1 BRCA2
8 tuberculous salpingitis 10.4 BRCA1 BRCA2
9 nosophobia 10.4 BRCA1 BRCA2
10 cancerophobia 10.4 BRCA1 BRCA2
11 breast-ovarian cancer, familial 1 10.4 BRCA1 BRCA2
12 uterine corpus serous adenocarcinoma 10.4 BRCA1 BRCA2
13 lynch syndrome i 10.4 BRCA1 BRCA2
14 fallopian tube adenocarcinoma 10.4 BRCA1 BRCA2
15 synchronous bilateral breast carcinoma 10.4 BRCA1 BRCA2
16 peritoneum cancer 10.4 BRCA1 BRCA2
17 glycogen-rich clear cell breast carcinoma 10.4 BRCA1 BRCA2
18 clear cell adenofibroma 10.4 BRCA1 BRCA2
19 dysgerminoma of ovary 10.3 BRCA1 BRCA2
20 primary peritoneal carcinoma 10.3 BRCA1 BRCA2
21 bilateral breast cancer 10.3 BRCA1 BRCA2
22 mutagen sensitivity 10.3 BRCA1 BRCA2
23 pre-malignant neoplasm 10.3 BRCA1 BRCA2
24 fallopian tube carcinoma 10.3 BRCA1 BRCA2
25 malignant ovarian surface epithelial-stromal neoplasm 10.3 BRCA1 BRCA2
26 ovary epithelial cancer 10.3 BRCA1 BRCA2
27 hereditary breast ovarian cancer syndrome 10.3 BRCA1 BRCA2
28 breast carcinoma in situ 10.3 BRCA1 BRCA2
29 sporadic breast cancer 10.2 BRCA1 BRCA2
30 familial thyroid dyshormonogenesis 10.2 TG TPO
31 ductal carcinoma in situ 10.2 BRCA1 BRCA2
32 subacute lymphocytic thyroiditis 10.2 TG TPO
33 neonatal hypothyroidism 10.2 TG TPO
34 goiter, multinodular 1, with or without sertoli-leydig cell tumors 10.2 TG TPO
35 endemic goiter 10.2 TG TPO
36 plummer's disease 10.2 TG TPO
37 graves disease 1 10.2 TG TPO
38 hypothyroidism, congenital, nongoitrous, 4 10.2 TG TPO
39 myxedema 10.2 TG TPO
40 ovarian cancer 1 10.2 BRCA1 BRCA2
41 nontoxic goiter 10.2 TG TPO
42 subacute thyroiditis 10.2 TG TPO
43 pernicious anemia 10.2 TG TPO
44 hypothyroidism, thyroidal or athyroidal, with spiky hair and cleft palate 10.1 TG TPO
45 toxic diffuse goiter 10.1 TG TPO
46 female reproductive organ cancer 10.1 BRCA1 BRCA2
47 nodular goiter 10.1 TG TPO
48 autoimmune disease of endocrine system 10.1 TG TPO
49 thyroid gland disease 10.1 TG TPO
50 multinodular goiter 10.1 TG TPO

Graphical network of the top 20 diseases related to Premature Menopause:



Diseases related to Premature Menopause
Sources

Symptoms & Phenotypes for Premature Menopause

About this section

GenomeRNAi Phenotypes related to Premature Menopause according to GeneCards Suite gene sharing:

25
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability with cisplatin GR00101-A-4 8.96 BRCA1 BRCA2
2 Synthetic lethal with cisplatin GR00101-A-1 8.62 BRCA1 BRCA2

MGI Mouse Phenotypes related to Premature Menopause:

43
# Description MGI Source Accession Score Top Affiliating Genes
1 endocrine/exocrine gland MP:0005379 9.8 AMH BRCA1 BRCA2 POLG SYCE1 TG
2 homeostasis/metabolism MP:0005376 9.7 TG TPO AMH BRCA1 BRCA2 POLG
3 neoplasm MP:0002006 9.26 AMH BRCA1 BRCA2 POLG
4 reproductive system MP:0005389 9.02 AMH BRCA1 BRCA2 POLG SYCE1
Sources

Drugs & Therapeutics for Premature Menopause

About this section

Drugs for Premature Menopause (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 187)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Progesterone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Early Phase 1 57-83-0 5994
2
Estradiol Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 50-28-2 5757
3
Ethinyl Estradiol Approved Phase 4,Phase 3,Phase 2 57-63-6 5991
4
Norethindrone Approved Phase 4,Phase 2,Phase 3 68-22-4 6230
5
Ganirelix Approved Phase 4 124904-93-4, 123246-29-7 25081094
6
Leuprolide Approved, Investigational Phase 4,Phase 2 53714-56-0 657181 3911
7
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
8
Lenograstim Approved, Investigational Phase 4 135968-09-1
9
Lactitol Investigational Phase 4 585-86-4 3871
10 Estrogens Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
11 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1
12 Hormones Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
13 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1
14 Contraceptive Agents Phase 4,Phase 3,Phase 2,Phase 1
15 Contraceptives, Oral Phase 4,Phase 2,Phase 3
16 Estradiol 17 beta-cypionate Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
17 Estradiol 3-benzoate Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
18 Estradiol valerate Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 979-32-8
19 Norethindrone acetate Phase 4,Phase 2,Phase 3
20 Norethindrone acetate, ethinyl estradiol, ferrous fumarate drug combination Phase 4
21 Norinyl Phase 4
22 Polyestradiol phosphate Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
23 Progestins Phase 4,Phase 3,Phase 2,Early Phase 1
24 Chorionic Gonadotropin Phase 4
25 Antineoplastic Agents, Hormonal Phase 4,Phase 3,Phase 2,Phase 1
26 Deslorelin Phase 4,Phase 2,Phase 3
27 Luteolytic Agents Phase 4,Phase 3,Phase 2
28 Triptorelin Pamoate Phase 4,Phase 3,Phase 2
29 Neurotransmitter Agents Phase 4,Phase 3,Phase 1,Phase 2
30 Central Nervous System Stimulants Phase 4,Phase 1,Phase 2
31 Dopamine Agents Phase 4
32 Dopamine Uptake Inhibitors Phase 4
33 Lisdexamfetamine Dimesylate Phase 4
34 Neurotransmitter Uptake Inhibitors Phase 4
35 Adjuvants, Immunologic Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
36 Hypoglycemic Agents Phase 4
37 insulin Phase 4
38 Insulin, Globin Zinc Phase 4
39
Testosterone Approved, Investigational Phase 3,Phase 2,Phase 1 58-22-0 6013
40
Cyclophosphamide Approved, Investigational Phase 3,Phase 2 50-18-0, 6055-19-2 2907
41
Goserelin Approved Phase 3 65807-02-5 5311128 47725
42
Doxorubicin Approved, Investigational Phase 3 23214-92-8 31703
43
Epirubicin Approved Phase 3 56420-45-2 41867
44
Fluorouracil Approved Phase 3 51-21-8 3385
45
Methotrexate Approved Phase 3 1959-05-2, 59-05-2 126941
46
Paclitaxel Approved, Vet_approved Phase 3 33069-62-4 36314
47
Gabapentin Approved, Investigational Phase 3 60142-96-3 3446
48
gamma-Aminobutyric acid Approved, Investigational Phase 3 56-12-2 119
49
Triamcinolone Approved, Vet_approved Phase 3 124-94-7 31307
50
Dacarbazine Approved, Investigational Phase 3 4342-03-4 5351166

Interventional clinical trials:

(show top 50) (show all 181)

# Name Status NCT ID Phase Drugs
1 Effects of ADSC Therapy in Women With POF Unknown status NCT01853501 Phase 4
2 Evaluation of Physiologic and Standard Sex Steroid Replacement Regimens in Women With Premature Ovarian Failure Completed NCT00732693 Phase 4 Ethinylestradiol / Norethisterone;Estradiol / Progesterone
3 Modified Natural Cycle Offers a Chance of Pregnancy in Patients With Poor Response and High Basal FSH Completed NCT00417157 Phase 4 recombinant FSH (Puregon, Organon, The Netherlands);GnRH antag: Ganirelix (Orgalutran, Organon, The Netherlands);hCG (Pregnyl, Organon, The Netherlands)
4 Flexible GnRH Antagonist vs Flare up GnRH Agonist Protocol in Poor Responders Completed NCT00417066 Phase 4 Ganirelix 0.25mg (Orgalutran, Organon, The Netherlands);Arvekap 0.1mg (Triptorelin, Ipsen, France)
5 Estrogen Dosing in Turner Syndrome: Pharmacology and Metabolism Completed NCT00837616 Phase 4 17 B estradiol orally;17 B estradiol
6 Long-Term Growth and Skeletal Effects of Early Growth Hormone Treatment in Turner Syndrome Completed NCT00266656 Phase 4 Humatrope
7 Defining the Optimal Hormonal Replacement Therapy in Turner Syndrome Completed NCT00134745 Phase 4 estradiol
8 A Study to Evaluate Subjects With Turner Syndrome Treated With Growth Hormone Completed NCT00097552 Phase 4
9 Growth Response in Girls With Turner Syndrome Completed NCT01734486 Phase 4 somatropin;somatropin
10 Safety of Somatropin and Induction of Puberty With 17-beta-oestradiol in Girls With Turner Syndrome Completed NCT01518062 Phase 4 somatropin;somatropin;somatropin;oestrogen
11 Growth Hormone Treatment for the Prevention of Short Stature in Young Girls With Turner Syndrome Before the Age of 4 Years Completed NCT01066052 Phase 4
12 First Year Growth Response Associated Genetic Markers Validation Phase IV Open-label Study in Growth Hormone Deficient and Turner Syndrome Pre-pubertal Children: the PREDICT Pharmacogenetics Validation Study Completed NCT01419249 Phase 4
13 Bone Mineral Density (BMD) in Adolescents With Growth Hormone Deficiency (GHD) Completed NCT00097526 Phase 4
14 Norditropin NordiFlex® Device Compared to the Device Previously Used by Patients or Parents Completed NCT01245374 Phase 4
15 IMProving Executive Function Study Recruiting NCT03187353 Phase 4 Lisdexamfetamine;Placebo oral capsule
16 Evaluation of the Ease of Use, Preference, and Safety of EutropinPen Inj. Recruiting NCT03015909 Phase 4 Somatropin
17 Filgrastim for Premature Ovarian Insufficiency Active, not recruiting NCT02783937 Phase 4 Saline
18 Study to Identify Markers of Insulin Resistance During Growth Hormone Treatment for Short Stature Terminated NCT00121875 Phase 4 somatropin (rDNA)
19 Effect of Cetrorelex Acetate on Ovarian Function in Women Undergoing Chemotherapy Withdrawn NCT00507780 Phase 4 GnRH antagonist
20 Goserelin in Preventing Early Menopause in Premenopausal Women Undergoing Chemotherapy for Stage I, Stage II, or Stage III Breast Cancer Completed NCT00427245 Phase 3 cyclophosphamide;goserelin acetate
21 Triptorelin in Preventing Early Menopause in Premenopausal Women Who Are Receiving Chemotherapy for Stage I, Stage II, or Stage III Breast Cancer That Has Been Removed By Surgery Completed NCT00311636 Phase 3 cyclophosphamide;docetaxel;doxorubicin hydrochloride;epirubicin hydrochloride;fluorouracil;methotrexate;paclitaxel;triptorelin
22 Efficiency of Gonadotropin-releasing Hormone (GnRH) Agonist in Preventing Chemotherapy Induced Ovarian Failure Completed NCT01160315 Phase 2, Phase 3 Triptorelin;Norethisterone acetate
23 S0230 Goserelin in Preventing Ovarian Failure in Women Receiving Chemotherapy for Breast Cancer Completed NCT00068601 Phase 3 cyclophosphamide;goserelin acetate
24 Pilot Study Comparing Hypnotherapy and Gabapentin for Hot Flashes. Completed NCT00711529 Phase 3 gabapentin
25 Estrogen Treatment (Oral vs. Patches) in Turner Syndrome Completed NCT00140998 Phase 3 17 beta estradiol
26 Administration During Chemotherapy to Reduce Ovarian Failure Following Chemotherapy in Early Stage, Hormone-Receptor Negative Breast Cancer Completed NCT01530607 Phase 3 Standard cyclophosphamide;Goserelin (Zoladex)
27 An Open-Label, Multi-centre, Phase III Study of Local Tolerability of ZOMACTON 10MG Completed NCT00250250 Phase 3 ZOMACTON
28 Combination Chemotherapy in Treating Young Patients With Hodgkin's Lymphoma Completed NCT00433459 Phase 3 cyclophosphamide;dacarbazine;prednisolone;prednisone;procarbazine hydrochloride;vincristine sulfate
29 The Effect of Growth Hormone in Very Young Girls With Turner Syndrome Completed NCT00406926 Phase 3 Somatropin
30 Somatropin Treatment to Final Height in Turner Syndrome Completed NCT00191113 Phase 3 Somatropin;Ethinyl estradiol;Medroxyprogesterone acetate
31 The Effect of Androgen and Growth Hormone on Height and Learning in Girls With Turner Syndrome Completed NCT00029159 Phase 3 estrogen;androgen
32 Induction of Puberty With 17-beta Estradiol in Girls With Turner Syndrome Completed NCT01710696 Phase 3 17-beta estradiol;17-beta estradiol
33 Use of Somatropin in Turner Syndrome Completed NCT01518036 Phase 3 somatropin;somatropin
34 Evaluating Acceptance of New Liquid Somatropin Formulation in Children With Growth Hormone Deficiency Completed NCT01563926 Phase 3 somatropin
35 Study to Define Optimal IGF-1 Monitoring in Children Treated With NutropinAq Completed NCT00234533 Phase 3 Somatropin (rDNA origin)
36 Hormone Replacement for Premature Ovarian Insufficiency Recruiting NCT02922348 Phase 3 Hormone Replacement Therapy;Combined Oral Contraceptives
37 A Clinical Study to Assess the Efficacy and Safety of DA-3002 Active, not recruiting NCT01813630 Phase 3 DA-3002;Genotropin®
38 Dehydroepiandrosterone (DHEA) Treatment and Premature Ovarian Failure (POF) Terminated NCT00948857 Phase 2, Phase 3
39 Effect of Exercise and Phytoestrogen on Bone, Metabolic Syndrome Criteria and Complaints of the Early Menopause Terminated NCT00663104 Phase 3
40 Study of Oral Dehydroepiandrosterone(DHEA) to Treat Previously Unexplained Infertility Terminated NCT00650754 Phase 2, Phase 3
41 Goserelin Acetate Study for Ovarian Function in Patients With Primary Breast Cancer Terminated NCT00429403 Phase 3 Goserelin
42 Stem Cell Therapy Combined Hormone Replacement Therapy in Patients With Premature Ovarian Failure Unknown status NCT01742533 Phase 1, Phase 2 Hormone Replacement Therapy
43 Autologous Mesenchymal Stem Cells Transplantation In Women With Premature Ovarian Failure Unknown status NCT02062931 Phase 1, Phase 2
44 Autologous Stem Cells Transplantation in Patients With Idiopathic and Drug Induced Premature Ovarian Failure Unknown status NCT02043743 Phase 1, Phase 2
45 Pregnancy After Stem Cell Transplantation in Premature Ovarian Failure Completed NCT02151890 Phase 1, Phase 2
46 "It is a Real" The First Baby Of Autologous Stem Cell Therapy in Premature Ovarian Failure Completed NCT02372474 Phase 1, Phase 2
47 Hormone Replacement in Young Women With Premature Ovarian Failure Completed NCT00001951 Phase 2 TMTDS
48 Bioidentical 'Natural' Hormone Evaluation in Early Menopause Completed NCT00302731 Phase 2 Prempro, premarin, provera conjugated estrogens, medroxyprogesterone acetate;Estradiol , estriol , progesterone;estradiol,progesterone;estriol, progesterone
49 GnRH Analogue for Ovarian Function Preservation in Hematopoietic Stem Cell Transplantation Patients Completed NCT00429494 Phase 2 Leuprolide Acetate
50 Oxandrolone Compared With a Placebo on Growth Rate in Girls With Growth Hormone-Treated Turner's Syndrome Completed NCT00004275 Phase 2 growth hormone;oxandrolone

Search NIH Clinical Center for Premature Menopause

Inferred drug relations via UMLS 69 / NDF-RT 47 :


Cochrane evidence based reviews: menopause, premature

Sources

Genetic Tests for Premature Menopause

About this section
Sources

Anatomical Context for Premature Menopause

About this section

MalaCards organs/tissues related to Premature Menopause:

38
Breast, Bone, Ovary, Brain, Cortex, Testes, Liver
Sources

Publications for Premature Menopause

About this section

Articles related to Premature Menopause:

(show top 50) (show all 123)
# Title Authors Year
1
Identifying Biomarkers for Risk of Premature Menopause Among Childhood Cancer Survivors May Lead to Targeted Interventions and Wellness Strategies. ( 29432587 )
2018
2
A High-risk Haplotype for Premature Menopause in Childhood Cancer Survivors Exposed to Gonadotoxic Therapy. ( 29432556 )
2018
3
Nonsurgical premature menopause and reproductive implications in survivors of childhood cancer: A report from the Childhood Cancer Survivor Study. ( 29338081 )
2018
4
Ovarian ablation for premenopausal breast cancer: A review of treatment considerations and the impact of premature menopause. ( 28288389 )
2017
5
Prevalence and Determinants of Premature Menopause among Indian Women: Issues and Challenges Ahead. ( 28340231 )
2017
6
Dealing with premature menopause in women at high-risk for hereditary genital and breast cancer. ( 26928421 )
2016
7
Premature Menopause. ( 26316242 )
2015
8
Spanish consensus on premature menopause. ( 25578643 )
2015
9
Autosomal Translocation Patient Who Experienced Premature Menopause: A Case Report. ( 26356509 )
2015
10
Prevention of Premature Menopause and Preservation of Fertility in Young Cancer Survivors: Hopeful Though Modest Long-term Results. ( 26720024 )
2015
11
Managing premature menopause and sexual dysfunction. ( 26155020 )
2015
12
Hormone treatment may help prevent premature menopause in cancer patients. ( 26702070 )
2015
13
Symptoms, health behavior and understanding of menopause therapy in women with premature menopause. ( 24742007 )
2014
14
Premature menopause - Meeting the needs. ( 24879744 )
2014
15
Risk of premature menopause after treatment for Hodgkin's lymphoma. ( 25139687 )
2014
16
An interpretive description of chemotherapy-induced premature menopause among Latinas with breast cancer. ( 25158665 )
2014
17
Risk of premature menopause after treatment for Hodgkin's lymphoma. ( 25139688 )
2014
18
Premature menopause and risk of neurological disease: basic mechanisms and clinical implications. ( 24462786 )
2014
19
Impact of a premature menopause on cognitive function in later life. ( 24802975 )
2014
20
Frequency of premature menopause in women who carry a BRCA1 or BRCA2 mutation. ( 23414920 )
2013
21
Premature menopause. ( 23634337 )
2013
22
Premature menopause in young breast cancer: effects on quality of life and treatment interventions. ( 23819028 )
2013
23
Psychosocial adjustment in women with premature menopause: a cross-sectional survey. ( 22335389 )
2012
24
Premature menopause or early menopause and risk of ischemic stroke. ( 21993082 )
2012
25
A nationwide study on reproductive function, ovarian reserve, and risk of premature menopause in female survivors of childhood cancer: design and methodological challenges. ( 22917040 )
2012
26
Ovarian suppression for prevention of premature menopause and infertility: empty promise or effective therapy? ( 22231046 )
2012
27
Hormone replacement therapy and women with premature menopause--a cancer survivorship issue. ( 21561765 )
2011
28
Premature menopause and severity of coronary artery disease. ( 22279478 )
2011
29
Premature menopause: a comprehensive understanding of psychosocial aspects. ( 21854296 )
2011
30
Premature menopause or early menopause: long-term health consequences. ( 19733988 )
2010
31
Premature menopause is associated with increased risk of cerebral infarction in Japanese women. ( 20042893 )
2010
32
Premature menopause linked to CVD and osteoporosis. ( 20408329 )
2010
33
Menopause and sexuality: key issues in premature menopause and beyond. ( 20840281 )
2010
34
Premature menopause increases cardiovascular risk. ( 19811237 )
2009
35
Premature menopause: exploring the experience through online communication. ( 19298304 )
2009
36
The concept and treatment methodology for inducing ovulation in women in apparent premature menopause. ( 19688943 )
2009
37
Successful pregnancy with frozen embryo transfer into a gestational carrier from eggs obtained from a woman in premature menopause. ( 19860356 )
2009
38
HRT in premature menopause. ( 18796482 )
2008
39
Ovulation induction and pregnancy in a woman with premature menopause following gonadotropin suppression with the gonadotropin releasing hormone antagonist, cetrorelix--a case report. ( 18404830 )
2008
40
Treatment-related risk factors for premature menopause following Hodgkin lymphoma. ( 17890454 )
2008
41
Premature menopause: Article's recommendation of HRT is highly questionable. ( 18467384 )
2008
42
Premature menopause: Hormone replacement therapy is indeed indicated. ( 18497386 )
2008
43
"Coming to grips" with chemotherapy-induced premature menopause. ( 18389434 )
2008
44
Suspected premature menopause. ( 18403549 )
2008
45
Effect of premature menopause on sexuality. ( 19804022 )
2007
46
Management of premature menopause. ( 17448268 )
2007
47
Do survivors of childhood cancer have increased incidence of premature menopause? ( 17259929 )
2007
48
Treatment of premature menopause in breast cancer patients. ( 17685250 )
2007
49
Premature menopause in survivors of childhood cancer: a report from the childhood cancer survivor study. ( 16818852 )
2006
50
Premature menopause in patients with BRCA1 gene mutation. ( 16773440 )
2006
Sources

Variations for Premature Menopause

About this section
Sources

Expression for Premature Menopause

About this section
Search GEO for disease gene expression data for Premature Menopause.
Sources

Pathways for Premature Menopause

About this section

Pathways related to Premature Menopause according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Chks in Checkpoint Regulation 60
Show member pathways
 12.04 BRCA1 BRCA2 POLG
2
DNA Damage 4
11.8 BRCA1 BRCA2 POLG
3
Meiosis 62
Show member pathways
 11.6 BRCA1 BRCA2 SYCE1
4
Thyroxine (Thyroid Hormone) Production 1
9.4 TG TPO
Sources

GO Terms for Premature Menopause

About this section

Cellular components related to Premature Menopause according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 lateral element GO:0000800 8.62 BRCA1 BRCA2

Biological processes related to Premature Menopause according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cell cycle GO:0007049 9.62 BRCA1 BRCA2 SGO2 SYCE1
2 double-strand break repair GO:0006302 9.46 BRCA1 BRCA2
3 intrinsic apoptotic signaling pathway in response to DNA damage GO:0008630 9.43 BRCA1 BRCA2
4 DNA synthesis involved in DNA repair GO:0000731 9.4 BRCA1 BRCA2
5 response to gamma radiation GO:0010332 9.37 BRCA2 POLG
6 strand displacement GO:0000732 9.26 BRCA1 BRCA2
7 DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator GO:0006978 9.16 BRCA1 BRCA2
8 hormone biosynthetic process GO:0042446 8.96 TG TPO
9 chordate embryonic development GO:0043009 8.62 BRCA1 BRCA2
Sources

Sources for Premature Menopause

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....